XM does not provide services to residents of the United States of America.

Symrise beats Q1 sales expectations but lags peer



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 2-Symrise beats Q1 sales expectations but lags peer</title></head><body>

Includes shares, peer comparison in paragraphs 1-6

By Bartosz Dabrowski

April 25 (Reuters) -Symrise SY1G.DE beat first-quarter sales estimates on Thursday on higher demand but shares in the German flavour and fragrance maker fell as the result lagged behind Swiss peer Givaudan GIVN.S.

The stock was down 3.6% as of 0750 GMT afterSymrise's January-March revenue rose 5% in the reporting currency to 1.29 billion euros ($1.38 billion), above analysts' average forecast of 1.27 billion euros in a company-provided poll.

Like-for-like sales in its scent and care division grew 13.7% to 516.4 million euros, while the taste, nutrition and health business fell 0.1% to 775.2 million euros.

"The only negative was growth at Taste which was below expectations," Vontobel analyst Arben Hasanaj said. "Clearly, expectations by investors have been rising ever since Givaudan reported stellar results."

Swiss competitor Givaudan GIVN.S reported first-quarter sales above market expectations earlier this month, driven by improving volume demand and good business momentum.

Easing destocking trends are supporting flavour and fragrance makers' return to stable volumes after a wave of inventory reductions and lower demand weighed on volumes throughout last year.

Symrise, whose fragrances go into the perfumes of French luxury giants LVMH LVMH.PA and Kering PRTP.PA, said organic sales, which do not take currency effects into account, rose 10.9% in the quarter.

The group reaffirmedits 2024 and mid-term forecasts, including an earnings before interest, tax, depreciation and amortisation (EBITDA) margin of around 20% this year, annual sales growth of 5% to 7% until 2028 and an EBITDA margin of between 20% and 23% during the same period.

($1 = 0.9341 euros)



Reporting by Bartosz Dabrowski in Gdansk; Editing by Milla Nissi and Toby Chopra

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.